Company profile: Topas Therapeutics
1.1 - Company Overview
Company description
- Provider of nanoparticle-based therapeutics and the Topas Particle Conjugates platform to induce antigen-specific immune tolerance by harnessing the liver’s tolerogenic power, targeting autoimmune and antigen-driven diseases (including allergies and anti-drug antibodies), with clinical candidates TPM203 (Phase 1) for pemphigus vulgaris and TPM502 (Phase 2) for celiac disease.
Products and services
- Topas Particle Conjugates (TPCs) technology: A proprietary, liver-targeted platform that induces antigen-specific immune tolerance, harnessing the liver’s tolerogenic power to architect therapies for autoimmune and antigen-driven diseases
- TPM502: A Phase 2, nanoparticle-based clinical candidate for celiac disease that induces immune tolerance via Topas Particle Conjugates, advancing antigen-specific therapy for an autoimmune, antigen-driven condition
- TPM203: A Phase 1, nanoparticle-enabled clinical candidate for pemphigus vulgaris that induces antigen-specific immune tolerance using Topas’ technology to address this autoimmune blistering disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Topas Therapeutics
Vaporsens
HQ: United States
Website
- Description: Provider of nanofiber-based chemical sensing technology, developing a detector to help law enforcement, military, and public safety officials detect explosives and narcotics using a patent-pending sensor designed for high sensitivity and selectivity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaporsens company profile →
Genia Technologies
HQ: United States
Website
- Description: Provider of biotechnology leveraging biological nanopores for structure-based sequencing of single DNA molecules, aiming to reduce the price of genome sequencing toward the $100 genome and bring sequencing out of the lab into everyday use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genia Technologies company profile →
Transferra Nanosciences
HQ: Canada
Website
- Description: Provider of Chemistry Manufacturing and Controls services to biotechnology and pharmaceutical companies, specializing in the development and manufacture of complex drug delivery systems using lipid nanoparticle science.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transferra Nanosciences company profile →
Silence Therapeutics
HQ: United Kingdom
Website
- Description: Provider of RNA technology and a proprietary genetic medicine platform leveraging RNA interference to target and silence disease-associated genes without altering DNA. Developing siRNA therapies including zerlasiran (SLN360) to reduce high lipoprotein(a) and divesiran (SLN124) targeting TMPRSS6 to manage iron levels and treat polycythemia vera by increasing hepcidin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Silence Therapeutics company profile →
N4 Pharma
HQ: United Kingdom
Website
- Description: Provider of drug reformulation solutions, developing and out-licensing new versions of existing and novel high-value drugs for unmet needs. Advances products to clinical proof of concept then partners for regulatory. Offerings include Nuvec, a silica nanoparticle system to protect and deliver siRNA, RNA, and DNA; LipTide, a lipid and peptide-based platform that mimics a natural virus for targeted RNA delivery; and ECP105, an siRNA therapy for post-surgical glaucoma by silencing MRTF-B.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full N4 Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Topas Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Topas Therapeutics
2.2 - Growth funds investing in similar companies to Topas Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Topas Therapeutics
4.2 - Public trading comparable groups for Topas Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →